Diabetes Drugs Market Size & Industry Outlook
The global diabetes drugs market size reached US$ 85.21 billion in 2025, up from US$ 80.75 billion in 2024, and is expected to reach US$ 125.36 billion by 2033, growing at a CAGR of 4.83% during the forecast period 2026-2033.
The diabetes drugs market is witnessing steady growth due to the rising global burden of diabetes, increasing awareness of early diagnosis, and the growing need for long-term blood glucose management. The market includes a wide range of therapies such as insulin, GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, and combination drugs, serving patients with both type 1 and type 2 diabetes. Demand is being supported by changing lifestyles, rising obesity rates, aging populations, and improved access to treatment across developing and developed regions. Pharmaceutical companies are increasingly focusing on innovative formulations, once-weekly therapies, oral biologics, and combination treatments that improve patient convenience and adherence. In addition, advancements in drug delivery systems, such as insulin pens and smart injectors, are strengthening treatment adoption. Growing healthcare expenditure, supportive government initiatives, and expanding diabetic care infrastructure are also contributing to market expansion, while competition continues to intensify with the launch of more effective and patient-friendly therapies.
Diabetes Drugs Market Key Takeaways
- North America dominates the diabetes drugs market with the largest revenue share of 44.61% in 2024.
- The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 9.7% over the forecast period.
- Based on drug class, the GLP-1 receptor agonists segment led the market with the largest revenue share of 41.32% in 2024.
- The major market players in the diabetes drugs market are Eli Lilly and Company, Novo Nordisk, Merck & Co., Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Sanofi, AstraZeneca, Takeda Pharmaceutical Company Limited, and Novartis AG, among others
Diabetes Drugs Market Dynamics
Drivers: Rising incidence of cancer cases is significantly driving the Diabetes Drugs market growth
The rising prevalence of diabetes is one of the most powerful forces driving the growth of the global diabetes drugs market, creating sustained demand for innovative and accessible therapies. According to the International Diabetes Federation (IDF), the global diabetic population stood at 537 million adults in 2021 and is expected to reach 643 million by 2030 and 783 million by 2045, reflecting a staggering 46% increase within two decades.
This surge is largely attributed to sedentary lifestyles, obesity, unhealthy dietary habits, and population aging, particularly in emerging economies such as India and China, which together account for more than one-third of global diabetes cases. As the diabetic population expands, especially in low- and middle-income nations, the diabetes drugs market is poised for robust, sustained growth driven by the urgent global need for effective, long-term disease management solutions.
Restraints: The high cost of advanced therapies is hampering the growth of the market
The high cost of advanced diabetes therapies is a significant barrier restraining the growth of the global diabetes drugs market, limiting accessibility and adherence among patients. Innovative treatments such as GLP-1 receptor agonists and dual agonists including Ozempic (semaglutide) and Mounjaro (tirzepatide). The cost of Ozempic 0.25 or 0.5 mg (1 x 1.5-mL pen) is $997.58, Ozempic 1 mg (1 x 3-mL pen) costs $997.58, and Ozempic 2 mg (1 x 3-mL pen) costs $997.58, making them unaffordable for many without comprehensive insurance coverage.
Even in developed markets, patients face high co-payments and insurance restrictions, while in low- and middle-income countries, these drugs are often completely out of reach. The affordability gap widens as demand for these drugs also extends to obesity management, increasing strain on supply and pricing. Traditional insulins and generics remain cheaper alternatives, but they lack the additional weight and cardiovascular benefits of newer drugs. This cost disparity discourages early adoption, particularly in public healthcare systems, which often prioritize cost-effective generics.
For more details on this report – Request for Sample
List of Some Key Approved Drugs
Epidemiology Analysis
Diabetes Drugs Market, Segment Analysis
The global diabetes drugs market is segmented based on drug, class, application, route of administration, distribution channel, and region.
Drug Class: The GLP-1 receptor agonists segment is dominating the diabetes drugs market with a 41.32% share in 2024
The GLP-1 receptor agonists segment has emerged as the dominant and fastest-growing segment in the global diabetes drugs market, reshaping the competitive landscape of diabetes care. These drugs, which mimic the body’s natural incretin hormones to enhance insulin secretion, suppress appetite, and promote weight loss, offer dual benefits for glycemic control and obesity management, a combination driving massive adoption.
Leading brands such as Novo Nordisk’s Ozempic (semaglutide) and Eli Lilly’s Trulicity (dulaglutide) have become blockbuster products, with Ozempic generated USD 4,485.25 million in 2024 sales and Trulicity generated USD 5,253.5 million, reflecting unprecedented demand. The launch of Eli Lilly’s Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist has further accelerated market momentum, achieving record-breaking adoption.
The rising use of GLP-1s in obesity management, alongside diabetes treatment, has expanded their market reach beyond traditional diabetic populations. Moreover, their favorable cardiovascular and renal outcomes, validated in major clinical trials, have strengthened their position in treatment guidelines and insurance coverage.
Pharmaceutical giants like Novo Nordisk and Eli Lilly are ramping up production capacity to meet global shortages, particularly in North America and Europe. Overall, the GLP-1 receptor agonist class is not only dominating the diabetes drugs market but also redefining its future trajectory through innovation, therapeutic versatility, and surging global demand.
The SGLT2 inhibitors segment is the fastest-growing in the diabetes drugs market with a 17.81% share in 2024
The SGLT2 inhibitors segment (sodium-glucose cotransporter 2 inhibitors) is widely recognised as the fastest-growing class within the diabetes drugs market. First, SGLT2 inhibitors such as Jardiance (empagliflozin) and Farxiga (dapagliflozin) have expanded far beyond glycaemic control in type 2 diabetes to treat cardiovascular disease (CVD) and chronic kidney disease (CKD). For instance, Jardiance was approved by the U.S. Food and Drug Administration (FDA) in September 2023 for the treatment of adults with CKD, reducing risk of kidney-disease progression and cardiovascular death.
Similarly, the clinical evidence supporting SGLT2 inhibitors is compelling, trials like EMPA-KIDNEY and others have shown meaningful reductions in hospitalization for heart failure, CKD progression, and cardiovascular events. This broadening of indications means the patient base for SGLT2 inhibitors now spans diabetics and non-diabetics with heart or kidney disease.
Diabetes Drugs Market, Geographical Analysis
North America is expected to dominate the global diabetes drugs market with a 44.61% in 2024
North America dominates the global diabetes drugs market because it combines a high disease burden, deep payer markets, rapid uptake of premium therapies, and a favorable regulatory and commercialization ecosystem. The US alone has roughly 38.4 million people with diabetes (≈11.6% of the population), producing a large, clinically managed patient base that drives chronic drug demand.
US Diabetes Drugs Market Trends
Rapid regulatory approvals and an active FDA pathway for new antidiabetic and weight-management agents have accelerated product launches and label expansions. For instance, in October 2025, MannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) seeking approval for Afrezza (insulin human) Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes. The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2026.
Similarly, in April 2025, Meitheal Pharmaceuticals secured approval from the US Food and Drug Administration (FDA) for its liraglutide injection (18mg/3mL), a generic equivalent of Victoza, and has commenced its distribution in the US.
Major pharma players, notably Novo Nordisk, Eli Lilly, and Sanofi have concentrated commercial operations, manufacturing scale, and patient-support programs in North America, with blockbuster GLP-1 franchises fueling revenue growth; for instance, Novo Nordisk reports very large semaglutide-family sales tied heavily to North American demand.
The Asia Pacific region is the fastest-growing region in the global diabetes drugs market, with a CAGR of 9.7% in 2024
The Asia‑Pacific region is the fastest-growing market in the global diabetes drugs landscape, driven by a combination of high unmet need, rapid urbanisation and favourable demographics. For instance, the International Diabetes Federation reports that the Western Pacific sub-region alone had approximately 215 million adults aged 20–79 years with diabetes in 2024, representing about 37 % of the global adult diabetic population.
Rising regulatory support for novel product approvals further driving the market growth in the region. For instance, in March 2025, American pharmaceutical major Eli Lilly and Company launched its diabetes and obesity management drug Mounjaro (tirzepatide) in India. The company launched the drug in a single-dose vial following marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO).
Similarly, partnerships and collaborations further accelerate the growth of the market by offering various top products in the market. For instance, in May 2025, Sumitomo Pharma Co., Ltd. announced that Sumitomo Pharma and Novo Nordisk Pharma Ltd. have entered into a co-promotion agreement in Japan for Ozempic Subcutaneous Injection 2 mg, a once-weekly subcutaneous GLP-1 receptor agonist indicated for the treatment of type 2 diabetes.
Europe Diabetes Drugs Market Trends
The diabetes drugs market in Europe is gaining strong momentum, driven by rising disease prevalence, regulatory approvals of innovative therapies, and increasingly favourable health-care infrastructure. In the World Health Organization European Region an estimated at least 64 million adults live with diabetes, with nearly one in ten Europeans likely to have the condition by 2045.
A key catalyst has been the approval of advanced drug classes in the region. For instance, in February 2025, Biocon launched its liraglutide products in the UK. The products are generic versions of Novo Nordisk’s Victoza, to treat type 2 diabetes, and Saxenda, used in the treatment of weight management. Biocon’s products are marketed under the brand names Liraglutide Biocon (gVictoza) and Biolide (gSaxenda). Biocon’s liraglutide became the first UK-approved generic to Novo Nordisk’s liraglutide products in March 2024.
Diabetes Drugs Market Competitive Landscape
Top companies in the diabetes drugs market include Eli Lilly and Company, Novo Nordisk, Merck & Co., Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Sanofi, AstraZeneca, Takeda Pharmaceutical Company Limited, and Novartis AG, Johnson & Johnson, Pfizer Inc., Takeda Pharmaceutical Company Limited among others.
Key Developments
August 2026: In North America, Eli Lilly continued gaining momentum in diabetes treatment as Mounjaro demand remained strong. The company also advanced its oral GLP-1 pipeline, intensifying competition with Novo Nordisk.
July 2026: In Europe, Eli Lilly’s Foundayo (orforglipron) expanded access as a once-daily oral option for type 2 diabetes and weight management, providing an alternative to injectable GLP-1 therapies.
June 2026: In Asia-Pacific, particularly China, Novo Nordisk continued strengthening its GLP-1 portfolio, while competition from Eli Lilly, Pfizer, and Innovent Biologics intensified in diabetes and metabolic disease treatments.
May 2026: In North America, Eli Lilly continued advancing orforglipron for diabetes following clinical results showing strong blood-glucose control compared with semaglutide, supporting its potential expansion beyond obesity treatment.
April 2026: Globally, diabetes drug development is increasingly focused on oral GLP-1 therapies, next-generation incretin drugs, improved glucose control, weight management, and convenient dosing. Novo Nordisk and Eli Lilly remained at the forefront of competition in the GLP-1 segment.
Diabetes Drugs Market Scope
| Metrics | Details | |
| CAGR | 4.83 % | |
| Market Size Available for Years | 2024-2033 | |
| Estimation Forecast Period | 2026-2033 | |
| Revenue Units | Value (US$ Bn) | |
| Segments Covered | Drug Class | GLP-1 Receptor Agonists, Insulins, SGLT2 Inhibitors, DPP-4 Inhibitors, Biguanides, and Others |
| Application | Type 2 Diabetes, Type 1 Diabetes, Gestational Diabetes, and Prediabetes | |
| Route of Administration | Injectable and Oral | |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies | |
| Regions Covered | North America, Europe, Asia-Pacific, South America and the Middle East & Africa | |
The global diabetes drugs market report delivers a detailed analysis with 64 key tables, more than 63 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
Suggestions for Related Report
For more pharmaceuticals-related reports, please click here
